Biomedical Research & Bio-Products

Biomedical Research & Bio-Products (Bio&Bio) is a Vienna-based biopharmaceutical company specializing in the development of vaccines and plasma-derived therapies. The company's lead program is a breakthrough vaccine against Staphylococcal-induced Toxic Shock Syndrome (TSS), which has successfully completed Phase 2 clinical trials. Bio&Bio is also developing a multi-component vaccine targeting sensitive and resistant Staphylococcus aureus (MRSA) infections and a hemostatic candidate, Prethrombin-1, for acute bleeding management. Founded in 2019 through a merger, the company leverages decades of expertise in coagulation and infectious disease research to address significant unmet medical needs. The company maintains strong academic ties, particularly with the Medical University of Vienna, to advance its clinical pipeline.